157 filings
Page 3 of 8
8-K
drcg2
15 Jun 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
w3zwf7j0lpoi8i 8hxo2
16 May 22
Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved
7:26am
8-K
nf4uo1m
16 May 22
Company preparing for Q4 commercial launch, if approved
7:14am
DEFA14A
3vrgxgo
28 Apr 22
Additional proxy soliciting materials
4:02pm
8-K
r1wofzy4il7bu1ru4
11 Apr 22
Anticipates Q4 2022 commercial launch, if approved
7:44pm
S-8
7rfx2trjbk77qn9
22 Mar 22
Registration of securities for employees
4:08pm
8-K
xk9afwgbnga5xm 907
22 Mar 22
Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved
7:11am
8-K
ux57esluu
9 Nov 21
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date
7:09am
8-K
2cs3s ey99g6lf
10 Sep 21
Heart Failure Society of America Annual Scientific Meeting 2021
8:12am
8-K
mbkjdb
11 Aug 21
Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs
7:07am
8-K
fh8gvgwuztp
14 Jul 21
Other Events
12:00am
8-K
yjxml2jh
1 Jul 21
FDA and Company in alignment on the path forward
8:10am
8-K
mn5otp7phb
9 Jun 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
oolbpc0nmoeggup0jr
12 May 21
FREEDOM clinical study on track for topline results in Q3 2021
8:06am